Modulation of noradrenaline release in human cardiovascular tissues.

M. Göthert

DOI: https://doi.org/10.1034/J.1600-0773.2003.920403.X

2003-04-01

Acta Pharmacologica et Toxicologica

Abstract:Continuous work during the last 35 years has established that noradrenaline (NA) release from postganglionic sympathetic axon terminals is modulated via an abundance of presynaptic autoand heteroreceptors and that modification of Ca2π influx plays a crucial role in this effect (Langer 1977; Starke 1977, 1981, 1987 & 2001; Westfall 1977). Important contributions to this field have been made by Ove Nedergaard both during the time which he spent in the laboratory of John Bevan (Nedergaard & Bevan 1969) and together with his coworkers in Odense (Storgaard & Nedergaard 1997; Jensen & Nedergaard 1999; Nedergaard 2000; Lomholt & Nedergaard 2000). In these investigations, mainly the rabbit pulmonary artery and aorta have been used. My group has sought an answer to the question whether the sites and mechanisms involved in the regulation of NA release, which have been identified and characterized in experiments on such animal preparations, are also operative in human cardiovascular tissue. A technique developed by Su & Bevan (1970) was the methodological backbone of our studies on superfused cardiovascular tissue (strips of atrial appendages, blood vessels and corpus cavernosum) preincubated with 3[H]NA in which the electrically evoked [3H]NA release was determined as a measure of action potential-induced release of endogenous NA. This short overview of our work will briefly touch upon Ca2π channels involved in NA release, on presynaptic modulatory receptors with special emphasis on 5-HT1B/1D receptors and on naturally occurring genetic variants of 5HT1B receptors.